Jan De Backer

Mar 27, 2024 | err.ersjournals.com | Simon Walsh |Jan De Backer |Vincent Cottin |Kevin Brown

Knowledge past and presentInterstitial lung diseases (ILDs) comprise a vast group of pulmonary disorders. All patients with idiopathic pulmonary fibrosis (IPF) and some patients with other fibrosing ILDs (fILDs) develop progressive pulmonary fibrosis (PPF), characterised by worsening of lung function, symptoms and quality of life, and high mortality [1]. fILDs have a variable clinical course [2–5].